Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02455245 · ClinicalTrials.gov registry record · Phase 3

A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma

A Phase 3 study of Low Grade Glioma, sponsored by Alicia Lenzen.

Active
Registry status
Phase 3
Development phase
95
Enrollment target
20
Study locations

NCT02455245 is a Phase 3 study of Low Grade Glioma that is active but no longer recruiting, run by Alicia Lenzen. The registered enrollment target is 95 participants, below the 110-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02455245, a Phase 3 study of Low Grade Glioma, is active but no longer recruiting, sponsored by Alicia Lenzen.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
95 participants
Enrollment target
20
Study locations

Study Summary

This study is trying to learn and understand if the chemotherapy drug called carboplatin works as well as the standard therapy. The standard therapy for Low Grade Glioma (LGG) in children and young adults is using a combination of carboplatin and vincristine. Studies in children have shown that the use of carboplatin alone has promise of being just as effective for treating LGG as standard therapy. Additionally, this study will try to understand if treatment with carboplatin alone is associated with an improved quality of life for LGG patients and their families.

Conditions Studied

Low Grade Glioma

Interventions

  • DRUG Carboplatin
  • DRUG Carboplatin and Vincristine

Study Locations (20)

Ohio

  • Children's Hospital Medical Center of Akron - Akron
  • Cincinnati Children's Hospital Medical Center - Cincinnati
  • Nationwide Children's Hospital - Columbus
  • Dayton Children's Hospital - Dayton

Missouri

  • Saint Louis University at SSM Cardinal Glennon Children's Medical Center - St Louis
  • Washington University School of Medicine - St Louis

Arizona

  • Phoenix Children's Hospital - Phoenix

California

  • Rady Children's Hospital - San Diego

Connecticut

  • Yale University - New Haven

Florida

  • Orlando Health, Inc. - Orlando

Illinois

  • Ann & Robert H. Lurie Children's Hosptial of Chicago - Chicago

Indiana

  • St. Vincent Peyton Manning Children's Hospital - Indianapolis

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2015-03
Est. Completion 2025-11-30
Phase Phase 3

Sponsor

Alicia Lenzen

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02455245

The ClinicalTrials.gov registry entry for NCT02455245 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 110-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (14% lower). The listed sponsor is Alicia Lenzen, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Low Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which Carboplatin is the first listed.

NCT02455245 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Ohio, Missouri, Arizona.

Frequently Asked Questions

What is clinical trial NCT02455245 about?

NCT02455245 is a clinical study titled "A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma". This study is trying to learn and understand if the chemotherapy drug called carboplatin works as well as the standard therapy. The standard therapy for Low Grade Glioma (LGG) in children and young adults is using a combination of carboplatin and vincristine. Studies in children have shown that the ...

What is the current status of trial NCT02455245?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 95 participants. The study started on 2015-03. Estimated completion is 2025-11-30.

What conditions does trial NCT02455245 study?

This clinical trial studies the following conditions: Low Grade Glioma.

What interventions are being tested in trial NCT02455245?

The interventions under investigation include: Carboplatin (DRUG), Carboplatin and Vincristine (DRUG).

Who is sponsoring clinical trial NCT02455245?

This trial is sponsored by Alicia Lenzen, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02455245 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Low Grade Glioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Low Grade Glioma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.